Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.02M$1.02Mderivedno prior Q4 2024 on file Net Income-$1.44M-$1.44MderivedN/M vs Q4 2024 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
Operating Incomederived-$1,471,268N/M Operating Cash Flowderived$1,444,264−72.8% Free Cash Flowderived$1,237,623−73.9% Margins · derivedOperating margin-143.7%
Net margin-140.8%
ended Dec 31, 2025 · filed Mar 26, 2026 · 85 d after period end